Maryann Selfe
Helping investors decide where and how to invest in the emerging women's health opportunity.






Across Credit Suisse (later UBS), a long institutional track record of investing capital in public and private investments, building investment portfolios, and structuring complex cross-border investment solutions.
20+ years
In institutional investment management
1,000+
Managers reviewed
$100bn+
Investment risk oversight
That experience now informs a focus on women's health and healthcare technology, where scientific progress and overlooked needs are creating opportunities for investment.

She saw the blindspot.
The Billion Dollar Blindspot
Why Women's Health Is the Investment Opportunity of Our Time
The book puts women's health firmly in the investment conversation. Continuing research follows the science, companies and capital shaping the opportunity.
She gave the conviction a name.
The potential value created when a more precise understanding of biology, clinical needs and lived experience leads to better healthcare and durable businesses.
Women's health is a leading edge of this broader healthcare transition.
Coined by Maryann Selfe, The Precision Premium is the thesis behind Calabar Capital.
Now she's putting capital behind it.
Investing in women's health and healthcare technology through specialist venture funds and direct co-investments.
An original thesis, backed by institutional investment discipline and a diversified approach.
Bringing the women's health investment opportunity to institutional investors, family offices and healthcare leaders through international keynotes, executive briefings and media commentary.
Selected forums




Convening the people moving the field forward.
An independent nonprofit founded to bring together investors, specialist fund managers, healthcare leaders, founders, clinicians and researchers advancing women's health.
Connecting the people building the solutions with the expertise and capital that can help them scale.
Research and investment perspectives from The Billion Dollar Blindspot.
Subscribe on Substack